Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03133156
Other study ID # 2016-33
Secondary ID R01DK112283
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 15, 2017
Est. completion date January 1, 2026

Study information

Verified date January 2024
Source Joslin Diabetes Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether exercise training leads to changes in the white adipose tissue that are beneficial to the body's regulation of sugar and body weight.


Description:

The prevalence of obesity and type 2 diabetes in the United States and worldwide has risen dramatically over the last few decades, resulting in an enormous need for new therapies to treat these conditions. The discovery that beiging of subcutaneous white adipose tissue may increase energy expenditure has led to tremendous interest in beige cells as a potential treatment for diabetes and obesity. An established treatment for type 2 diabetes and obesity is endurance exercise training. Exercise training can improve systemic homeostasis, and although adaptations to skeletal muscle play a critical role in these effects, the underlying mechanisms are not fully understood. Moreover, the contributions of other tissues in these beneficial effects of exercise on metabolism have not been intensively investigated. The study team hypothesizes that exercise training results in fundamental changes to white adipose tissue, including beiging, and these adaptations play an important role in the effects of exercise training to improve metabolic homeostasis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 74
Est. completion date January 1, 2026
Est. primary completion date January 17, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: - Age: 25-55 years old at the time of screening - Body mass index (BMI) must be: - =20 and = 27 kg/m2 for lean subjects - =25 and = 37 kg/m2 for subjects with type 2 diabetes - =27 and = 37 kg/m2 for obese/overweight subjects - HbA1c values: - =5.7 ± 0.1% for lean and overweight/obese subjects - 6.5 ± 0.1% - 9.0 ± 0.1% for subjects with type 2 diabetes Exclusion Criteria: - Age <25 and >55 years old - Type 1 Diabetes - HbA1c = 9.0% - Heart or lung disease - Basal-Bolus Insulin regimen - Use of beta-blockers or thiazolidinediones - Acute systemic infection accompanied by fever, body aches, or swollen lymph glands - BMI = 37 kg/m2 - Current dieting or weight loss efforts - Current pregnant or breastfeeding - Known history of HIV/AIDS or certain cancers - Biochemical evidence of renal or hepatic dysfunction; renal or liver disease - Demyelinating diseases such as multiple sclerosis or amyotrophic lateral sclerosis - Recent blood donation - Clinical history of stroke - Severe hypertension (systolic > 160 mmHg or diastolic > 90 mmHg) - Inability to exercise at 50% of predicted heart rate (HR) reserve at baseline - Participants who screen positive for The American Heart Association's contraindications to exercise testing - History of keloid formation

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise Intervention
10-Week Aerobic Exercise Training

Locations

Country Name City State
United States Joslin Diabetes Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Joslin Diabetes Center National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in human adipose tissue characteristics following exercise training. Effects of exercise training on adipose tissue in humans. Change from baseline adipose tissue characteristics following 10 weeks of exercise training.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1